Over the past decade, several strains (types) of Salmonella typhi have become resistant to multiple antibiotics. Resistant strains have been identified across the globe. However, the 2018 launch of a vaccine has slowed infections. It is estimated that TCV introduction with a catch-up campaign will avert 42.5 million cases and 506,000 deaths caused by fluoroquinolone-resistant typhoid fever, and 21.2 million cases and 342,000 deaths from multidrug-resistant typhoid fever over 10 years following introduction. This episode will cover the impact of vaccinations and the challenges to deploy effective programs. 

Guests:

Farah Naz Qamar - Pediatric Infectious Disease Associate Professor, The Aga Khan University, Pakistan

Kathy Neuzil - Director of the Center for Vaccine Development and Global Health, University of Maryland School of Medicine

Denise Garrett - Vice President, Applied Epidemiology, Sabin Vaccine Institute

Calman MacLennan - Senior Program Officer, Bacterial Vaccines, Bill and Melinda Gates Foundation

For more information on the impact of typhoid conjugate vaccines and AMR, check out CIDRAP-ASP's report, A Vaccine Is a Bridge: The New Era of Typhoid Prevention.